69 related articles for article (PubMed ID: 27220685)
1. New psychoactive substances: catalysing a shift in forensic science practice?
Tettey J; Crean C
Philos Trans R Soc Lond B Biol Sci; 2015 Aug; 370(1674):. PubMed ID: 26101290
[TBL] [Abstract][Full Text] [Related]
2. Novel psychoactive substances (NPS) - knowledge and expe riences of drug users from Hungary, Poland, the UK and the USA.
Pisarska A; Deluca P; Demetrovics Z; Moskalewicz J; ReDNet G
Neuropsychopharmacol Hung; 2019 Dec; 21(4):152-163. PubMed ID: 32015192
[TBL] [Abstract][Full Text] [Related]
3. Legal highs: staying on top of the flood of novel psychoactive substances.
Baumeister D; Tojo LM; Tracy DK
Ther Adv Psychopharmacol; 2015 Apr; 5(2):97-132. PubMed ID: 26240749
[TBL] [Abstract][Full Text] [Related]
4. Acute kidney injury and critical limb ischaemia associated with the use of the so called "legal high" 3-fluorophenmetrazine.
Fawzy M; Wong-Morrow WS; Beaumont A; Farmer CKT
CEN Case Rep; 2017 Nov; 6(2):152-155. PubMed ID: 28711979
[TBL] [Abstract][Full Text] [Related]
5. Editorial: Old and new psychoactive substances: Pharmacology and potential applications.
Mayer FP; Luethi D; Areal LB; Sitte HH
Front Psychiatry; 2022; 13():1087005. PubMed ID: 36684007
[No Abstract] [Full Text] [Related]
6. Withdrawn: Predicting the lethal toxicity of psychoactive substances.
King LA
Drug Test Anal; 2022 Jun; 14(6):1170. PubMed ID: 33238076
[No Abstract] [Full Text] [Related]
7. Vasospasm due to ingestion of a combination of psychoactive substances: A case study.
Torres-Patiño IC; Fernandes-Pineda M; Ayala-Zapata S
Med Clin (Barc); 2024 Apr; ():. PubMed ID: 38688738
[No Abstract] [Full Text] [Related]
8. Ban fluorinated organic substances to spark green alternatives.
Sonne C; Xia C; Lam SS
Eco Environ Health; 2022 Jun; 1(2):105-106. PubMed ID: 38075526
[No Abstract] [Full Text] [Related]
9. Worldwide legislative challenges related to psychoactive drugs.
Negrei C; Galateanu B; Stan M; Balalau C; Dumitru MLB; Ozcagli E; Fenga C; Kovatsi L; Fragou D; Tsatsakis A
Daru; 2017 Jun; 25(1):14. PubMed ID: 28578694
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties.
Puigseslloses P; Nadal-Gratacós N; Ketsela G; Weiss N; Berzosa X; Estrada-Tejedor R; Islam MN; Holy M; Niello M; Pubill D; Camarasa J; Escubedo E; Sitte HH; López-Arnau R
Mol Psychiatry; 2024 Mar; ():. PubMed ID: 38486047
[TBL] [Abstract][Full Text] [Related]
11. Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act.
Kühnl R; Aydin D; Horn S; Olderbak S; Verthein U; Kraus L
Harm Reduct J; 2022 Nov; 19(1):122. PubMed ID: 36329471
[TBL] [Abstract][Full Text] [Related]
12. Physical Activity and Exercise Addiction During the Covid-19 Pandemic in Italy.
Ceci F; Di Carlo F; Burkauskas J; Salone A; De Luca I; Cicconcelli D; Giorgetti V; La Fratta I; Todaro A; Simonato P; Martinotti G; di Giannantonio M; Corazza O
Int J Ment Health Addict; 2022 Apr; ():1-21. PubMed ID: 35469185
[TBL] [Abstract][Full Text] [Related]
13. Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.
Deen AA; Claridge H; Treble RD; Hamnett HJ; Copeland CS
J Psychopharmacol; 2021 Nov; 35(11):1315-1323. PubMed ID: 34182812
[TBL] [Abstract][Full Text] [Related]
14. New psychoactive substances: a review and updates.
Shafi A; Berry AJ; Sumnall H; Wood DM; Tracy DK
Ther Adv Psychopharmacol; 2020; 10():2045125320967197. PubMed ID: 33414905
[TBL] [Abstract][Full Text] [Related]
15. Understanding the UK Psychoactive Substances Act.
Hill RG
Br J Clin Pharmacol; 2020 Mar; 86(3):499-504. PubMed ID: 31749206
[TBL] [Abstract][Full Text] [Related]
16. The emergence of Exercise Addiction, Body Dysmorphic Disorder, and other image-related psychopathological correlates in fitness settings: A cross sectional study.
Corazza O; Simonato P; Demetrovics Z; Mooney R; van de Ven K; Roman-Urrestarazu A; Rácmolnár L; De Luca I; Cinosi E; Santacroce R; Marini M; Wellsted D; Sullivan K; Bersani G; Martinotti G
PLoS One; 2019; 14(4):e0213060. PubMed ID: 30943200
[TBL] [Abstract][Full Text] [Related]
17. Health and Social Problems Associated with Recent Novel Psychoactive Substance (NPS) Use Amongst Marginalised, Nightlife and Online Users in Six European Countries.
Van Hout MC; Benschop A; Bujalski M; Dąbrowska K; Demetrovics Z; Felvinczi K; Hearne E; Henriques S; Kaló Z; Kamphausen G; Korf D; Silva JP; Wieczorek Ł; Werse B
Int J Ment Health Addict; 2018; 16(2):480-495. PubMed ID: 29674947
[TBL] [Abstract][Full Text] [Related]
18. Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill.
Reuter P; Pardo B
Addiction; 2017 Jan; 112(1):25-31. PubMed ID: 27220685
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
